Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis.


There is increasing evidence that toxicity of mutant superoxide dismutase-1 (SOD1) in amyotrophic lateral sclerosis (ALS) is linked to its propensity to misfold and to aggregate. Immunotargeting of differently folded states of SOD1 has provided therapeutic benefit in mutant SOD1 transgenic mice. The specific region(s) of the SOD1 protein to which these… (More)
DOI: 10.1523/JNEUROSCI.5053-11.2012

6 Figures and Tables


  • Presentations referencing similar topics